| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/07/2013 | US20130059887 Substituted pyridoxine-lactam carboxylate salts |
| 03/07/2013 | US20130059883 Compounds and methods |
| 03/07/2013 | US20130059879 Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics |
| 03/07/2013 | US20130059878 Treatment of diseases modulated by a h4 receptor agonist |
| 03/07/2013 | US20130059877 Treatment of solid tumors with rapamycin derivatives |
| 03/07/2013 | US20130059867 Salt of fused heterocyclic derivative and crystal thereof |
| 03/07/2013 | US20130059862 Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof |
| 03/07/2013 | US20130059861 Method for inducing tumor apoptosis by increasing nitric oxide levels |
| 03/07/2013 | US20130059859 Predictive biomarkers for pi3k/akt kinase pathway inhibitor efficacy |
| 03/07/2013 | US20130059855 Crystal of di(arylamino)aryl compound |
| 03/07/2013 | US20130059853 Biaryl phosphodiesterase inhibitors |
| 03/07/2013 | US20130059852 Compounds for treating disease, for administering, and for pharmaceutical compositions |
| 03/07/2013 | US20130059851 Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy |
| 03/07/2013 | US20130059849 Azaindazoles |
| 03/07/2013 | US20130059847 Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| 03/07/2013 | US20130059843 Thiazolyl- and Oxazolyl-Isoquinolinones and Methods for Using Them |
| 03/07/2013 | US20130059839 Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use |
| 03/07/2013 | US20130059836 Pyrazolopyrimidine compounds for the treatment of cancer |
| 03/07/2013 | US20130059835 Heterocyclylamines as pi3k inhibitors |
| 03/07/2013 | US20130059834 Pyrrolopyrazine kinase inhibitors |
| 03/07/2013 | US20130059816 Compositions and methods for treatment of autoimmune and other disease |
| 03/07/2013 | US20130059800 Pyrrolobenzodiazepines used to treat proliferative diseases |
| 03/07/2013 | US20130059794 Alpha-fetoprotein "ring and tail" peptides |
| 03/07/2013 | US20130059792 Traceability of Cellular Cycle Ano |
| 03/07/2013 | US20130059788 Prodomain modulators of adam 10 |
| 03/07/2013 | US20130059787 Methods of using human protein kinase c delta viii as a biomarker |
| 03/07/2013 | US20130059771 Function and Regulation of Angiopoietin-3/Angiopoietin-4 |
| 03/07/2013 | US20130059769 Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
| 03/07/2013 | US20130059018 Phytocannabinoids in the treatment of cancer |
| 03/07/2013 | US20130059015 Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response |
| 03/07/2013 | US20130059004 Oral drug delivery system |
| 03/07/2013 | US20130058998 Encapsulated n-acetylmannosamine or n-acetylneuraminic acid to increase sialylation |
| 03/07/2013 | US20130058996 LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF |
| 03/07/2013 | US20130058992 Gene expression signatures associated with response to imatinib mesylate in gastrointestinal stromal tumors and use thereof for predicting patient response to therapy and identification of agents which have efficacy for the treatment of cancer |
| 03/07/2013 | US20130058984 Single-walled carbon nanotube/bioactive substance complexes and methods related thereto |
| 03/07/2013 | US20130058980 Small molecule inhibitors of protein kinases |
| 03/07/2013 | US20130058979 Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
| 03/07/2013 | US20130058966 Anti-pdef antibodies and uses thereof |
| 03/07/2013 | US20130058965 Injectable formulations for parenteral administration |
| 03/07/2013 | US20130058964 Methods for activating t cells and modulating an immune response |
| 03/07/2013 | US20130058962 Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| 03/07/2013 | US20130058960 Compositions and methods for the diagnosis and treatment of tumor |
| 03/07/2013 | US20130058959 Hematopoietic cell selectin ligand polypeptides and methods of use thereof |
| 03/07/2013 | US20130058957 Dendritic cell immunoreceptor agonist |
| 03/07/2013 | US20130058955 Anti-polyubiquitin antibodies and methods of use |
| 03/07/2013 | US20130058948 Antibodies Directed To Gpnmb And Uses Thereof |
| 03/07/2013 | US20130058947 Novel Modulators and Methods of Use |
| 03/07/2013 | US20130058942 Human beta-adrenergic receptor kinase polypeptide and methods |
| 03/07/2013 | US20130058938 Gna11 mutations in melanoma |
| 03/07/2013 | US20130058937 Bispecific antigen binding molecules |
| 03/07/2013 | US20130058936 Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| 03/07/2013 | US20130058935 Antibodies to tumor endothelial marker 7r |
| 03/07/2013 | US20130058934 Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| 03/07/2013 | US20130058932 Use of pkc-iota inhibitors for the treatment of glioma |
| 03/07/2013 | US20130058927 Anti-vegf antibodies |
| 03/07/2013 | US20130058925 Epithelial biomarkers for cancer prognosis |
| 03/07/2013 | US20130058924 Hypoxia-related gene signatures for cancer classification |
| 03/07/2013 | US20130058922 Pharmaceutical composition containing choline |
| 03/07/2013 | US20130058921 Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| 03/07/2013 | US20130058920 METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE |
| 03/07/2013 | US20130058919 Optimized Fc Variants and Methods for their Generation |
| 03/07/2013 | US20130058908 High affinity ny-eso t cell receptors |
| 03/07/2013 | US20130058899 Cancer Therapy with a Parvovirus Combined with an HDAC Inhibitor |
| 03/07/2013 | US20130058897 Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same |
| 03/07/2013 | US20130058896 Compositions and methods related to anti-fgf agents |
| 03/07/2013 | US20130058893 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 03/07/2013 | US20130058892 Pyrimidinyl indole compounds |
| 03/07/2013 | US20130058876 (trimethoxyphenylamino) pyrimidinyl formulations |
| 03/07/2013 | US20130058873 P97 fragments with transfer activity |
| 03/07/2013 | US20130058871 Method and system for mapping synaptic connectivity using light microscopy |
| 03/07/2013 | US20130058870 3d nanocrystals and manufacturing methods |
| 03/07/2013 | US20130058868 Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
| 03/07/2013 | US20130058864 Antibodies that bind ov064 and methods of use therefor |
| 03/07/2013 | US20130058863 4-Protein Biomarker Panel for the Diagnosis of Lymphoma from Biospecimen |
| 03/07/2013 | CA2847336A1 Glycosylated polypeptide and drug composition containing said polypeptide |
| 03/07/2013 | CA2847334A1 Glycosylated polypeptide and drug composition containing said polypeptide |
| 03/07/2013 | CA2847332A1 Vaccine preparation for cancer treatment |
| 03/07/2013 | CA2847283A1 Organic compositions to treat hsf1-related diseases |
| 03/07/2013 | CA2847017A1 Selective and reversible inhibitors of ubiquitin specific protease 7 |
| 03/07/2013 | CA2847001A1 Use of compositions having a low polyamine content in the prevention or treatment of adverse effects linked to cancer treatment |
| 03/07/2013 | CA2846865A1 Use of hdl-related molecules to treat and prevent proinflammatory conditions |
| 03/07/2013 | CA2846852A1 Fap-activated proteasome inhibitors for treating solid tumors |
| 03/07/2013 | CA2846692A1 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines |
| 03/07/2013 | CA2846652A1 Heterocyclylamines as pi3k inhibitors |
| 03/07/2013 | CA2846574A1 Certain chemical entities, compositions, and methods |
| 03/07/2013 | CA2846429A1 Parp inhibitors |
| 03/07/2013 | CA2846287A1 Stable peptide-based pace4 inhibitors |
| 03/07/2013 | CA2846272A1 Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone |
| 03/07/2013 | CA2846248A1 Method for inhibiting cellular activation by insulin-like growth factor-1 |
| 03/07/2013 | CA2846218A1 Peptides |
| 03/07/2013 | CA2845585A1 Decitabine derivative formulations |
| 03/07/2013 | CA2844993A1 Platinum anticancer agents |
| 03/07/2013 | CA2844464A1 Methods for treating properdin-related diseases or disorders |
| 03/06/2013 | EP2565278A1 Method for the delivery of oligonucleotides |
| 03/06/2013 | EP2565268A1 Novel muc1 antibody |
| 03/06/2013 | EP2565203A1 Peptide vaccines having Seq ID: 344v for cancers expressing tumor-associated antigens |
| 03/06/2013 | EP2565192A1 Anticancer agent |
| 03/06/2013 | EP2565188A1 Novel photoactivatable paclitaxel derivatives and uses thereof, in particular in cellbiology and cancer treatment |
| 03/06/2013 | EP2565186A1 Selective and reversible inhibitors of ubiquitin specific protease 7 |
| 03/06/2013 | EP2565180A2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same |